Cargando…

Viral and Symptom Rebound in Untreated COVID-19 Infection

BACKGROUND: There are reports of viral RNA and symptom rebound in people with COVID-19 treated with nirmatrelvir/ritonavir. Since the natural course of viral and symptom trajectories of COVID-19 has not been well described, we evaluated the incidence of viral and symptom rebound in untreated outpati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deo, Rinki, Choudhary, Manish C., Moser, Carlee, Ritz, Justin, Daar, Eric S., Wohl, David A., Greninger, Alexander L., Eron, Joseph J., Currier, Judith S., Hughes, Michael D., Smith, Davey M., Chew, Kara W., Li, Jonathan Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387151/ https://www.ncbi.nlm.nih.gov/pubmed/35982660 http://dx.doi.org/10.1101/2022.08.01.22278278

Ejemplares similares

Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody
por: Phan, Tin, et al.
Publicado: (2023)

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection
por: Boucau, Julie, et al.
Publicado: (2021)

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection
por: Boucau, Julie, et al.
Publicado: (2022)

Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials
por: Moser, Carlee B, et al.
Publicado: (2023)

881. Nasal and Plasma SARS-CoV-2 RNA Levels Predict Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19
por: Li, Yijia, et al.
Publicado: (2022)

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
por: Chew, Kara W., et al.
Publicado: (2022)

Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
por: Chew, Kara W., et al.
Publicado: (2023)

Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19
por: Moser, Carlee, et al.
Publicado: (2022)

Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses
por: Ramirez, Sydney I., et al.
Publicado: (2022)

Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19
por: Smith, Davey M., et al.
Publicado: (2022)

878. Association between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death for Non-Hospitalized Adults with Mild-to-Moderate COVID-19
por: Giganti, Mark, et al.
Publicado: (2022)

Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial
por: Chew, Kara W., et al.
Publicado: (2021)

LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
por: Evering, Teresa H, et al.
Publicado: (2021)

Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial
por: Jagannathan, Prasanna, et al.
Publicado: (2023)

Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials
por: Bender Ignacio, Rachel A., et al.
Publicado: (2023)

Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection
por: Bender Ignacio, Rachel A., et al.
Publicado: (2022)

To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017)

Vesicular MicroRNA as Potential Biomarkers of Viral Rebound
por: Bazié, Wilfried Wenceslas, et al.
Publicado: (2022)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Viral suppression and viral rebound among young adults living with HIV in Canada
por: Palmer, Alexis, et al.
Publicado: (2018)

Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features
por: Bartsch, Yannic C., et al.
Publicado: (2021)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?
por: Gousseff, Marie, et al.
Publicado: (2020)

Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race
por: Bhagwat, Priya, et al.
Publicado: (2018)

Potential biomarkers: Predicting post-treatment viral rebound in rhesus macaques
por: Yang, Chenbo, et al.
Publicado: (2023)

The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy
por: Huntington, Susie, et al.
Publicado: (2015)

Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
por: Hurst, Jacob, et al.
Publicado: (2015)

Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2018)

994. Risk for Viral Rebound in the Era of U=U; A CNICS Analysis
por: Hansen, Blake, et al.
Publicado: (2020)

Comment on: Rebound inflammation after an intravitreal injection in Vogt–Koyanagi–Harada syndrome
por: Jain, Manish
Publicado: (2018)

1609 Plasma markers of immune activation likely reflect related but distinct processes of cellular immune activation in HIV-infected persons before and after suppression of viremia by antiretroviral therapy: ACTG 5260
por: Kelesidis, Theodoros, et al.
Publicado: (2014)

Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers
por: Conway, Jessica M., et al.
Publicado: (2019)

Multidrug-resistant HIV viral rebound during early syphilis: a case report
por: Giacomelli, Andrea, et al.
Publicado: (2020)

A multidimensional HIV-1 persistence model for clonal expansion and viral rebound in vitro
por: Eshetu, Amare, et al.
Publicado: (2021)

Remdesivir/tocilizumab: Rebound of HCV viral load and loss of anti-HBs: case report
Publicado: (2021)

Unified model of short- and long-term HIV viral rebound for clinical trial planning
por: Conway, Jessica M., et al.
Publicado: (2021)

Factors associated with viral rebound among COVID-19 patients receiving oral antivirals
por: Chen, Pao-Yu, et al.
Publicado: (2023)

Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s
por: Dirajlal-Fargo, Sahera, et al.
Publicado: (2016)

Arsenic Trioxide Impacts Viral Latency and Delays Viral Rebound after Termination of ART in Chronically SIV‐Infected Macaques
por: Yang, Qing, et al.
Publicado: (2019)

SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
por: Edelstein, Gregory E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_es05psp4a4qh08dk10oe343bgm